Hematopoietic Growth Factors in Oncology

Basic Science and Clinical Therapeutics

  • George Morstyn
  • MaryAnn Foote
  • Graham J. Lieschke

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-x
  2. Basic Research

    1. Front Matter
      Pages 1-1
    2. George Morstyn, MaryAnn Foote
      Pages 3-10
    3. Ben A. Croker, Nicos A. Nicola
      Pages 45-64
    4. Ellen G. Laber, C. Glenn Begley
      Pages 65-80
  3. Hematopoietic Growth Factors

    1. Front Matter
      Pages 81-81
    2. Graham Molineux
      Pages 83-95
    3. Steven Elliott, Anne C. Heatherington, MaryAnn Foote
      Pages 97-123
    4. David J. Kuter
      Pages 125-151
    5. Keith E. Langley
      Pages 153-184
    6. Ann M. Farese, Thomas J. MacVittie
      Pages 185-207
  4. Use of Hematopoietic Growth Factors in Oncology

  5. Safety and Economic Implications

    1. Front Matter
      Pages 373-373
    2. Roy E. Smith, Barbara C. Good
      Pages 375-394
    3. Gary H. Lyman, Nicole M. Kuderer
      Pages 409-443
  6. Future Directions

    1. Front Matter
      Pages 445-445
    2. Hayley S. Ramshaw, Timothy R. Hercus, Ian N. Olver, Angel F. Lopez
      Pages 447-465
  7. Back Matter
    Pages 467-477

About this book


Whether to promote platelet recovery or to ameliorate the complications of cancer and the side effects of chemotherapy, hematopoietic growth factors (HGFs) now account for more than $5 billion per year of the US health care budget. In Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics, leading oncologists, hematologists, and nephrologists comprehensively review the role of HGFs in clinical practice, explain the molecular basis of their effects, and consider potential future developments. The authors focus on the use of HGFs in oncology, describing their cutting-edge application to patients with lung cancer, Hodgkin's and non-Hodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, AIDS-related malignancies, myelodysplastic syndromes, and aplastic anemias. Among the HGFs described are granulocyte colony-stimulating factor, erythropoietc factors, thrombopoietic factors, and stem-cell factor and its receptor, c-kit. To complete their survey, the contributors also consider the safety and economic implications of HGFs and the future potential for HGF antagonists in oncology.
Comprehensive and up-to-date, Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Practice offers an integrated survey of the role of HGFs in treating and preventing anemia, neutropenia, and thrombocytopenia in patients with malignant and nonmalignant diseases, along with fresh insights into drug development and how basic discoveries in this area can be optimally translated into clinical benefit.


anemia cell cytokines leukemia lymphoma pathology pharmacology stem cell

Editors and affiliations

  • George Morstyn
    • 1
  • MaryAnn Foote
    • 2
  • Graham J. Lieschke
    • 3
  1. 1.Amgen, Australia, Pty. Ltd.Monash UniversityAustralia
  2. 2.Amgen Inc.Thousand OaksUSA
  3. 3.Ludwig Institute for Cancer ResearchRoyal Melbourne HospitalMelbourneAustralia

Bibliographic information

Industry Sectors